NCT05825898

Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

Enrolling by Invitation
Not specifiedAges 18+Observational
Ottawa Heart Institute Research Corporation
~3,500 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Surgery or Transcatheter tricuspid valve intervention

At a glance

Recruiting sites
0 of 44 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Survival at 2 years
Measured over 2 years
Tricuspid Regurgitation
44 sites across 12 states
France12
Germany11
Spain5
New York3
Canada3
Switzerland3
Italy2
Minnesota1
  • David Messika-Zeitoun · PRINCIPAL_INVESTIGATOR · Ottawa Heart Institute Research Corporation

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Isolated (no left-valvular heart disease (mitral regurgitation) \>2)
AND Functional
AND Moderate to severe or severe Tricuspid regurgitation

Exclusion

Congenital valvular disease,
Previous tricuspid valve intervention,
Organic tricuspid valvular disease
Associated valvular heart disease
  • Survival at 2 years2 years

    Mortality